Avaleht › Müeloom › Nebraska › Omaha
Müeloom kliinilised uuringud linnas Omaha, NE
16 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Omaha ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Nebraska Cancer Specialists, Omaha
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- University of Nebraska Medical Center, Omaha
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
VärbamineFaas 1/2
- Nebraska Cancer Institute, Omaha
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Värbamine
- University of Nebraska Medical Center, Omaha
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
VärbamineFaas 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
VärbamineFaas 1
- University of Nebraska, Omaha
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 2
- University of Nebraska Medical Center, Omaha
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Värbamine
- Unversity of Nebraska Medical Center, Omaha
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- University Of Nebraska Medical Center, Omaha
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Halt Aging in Survivors of Blood Cancers
Värbamine
- University of Nebraska Medical Center, Omaha
Integrated Cancer Repository for Cancer Research
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- ja veel 1
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
VärbamineFaas 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
VärbamineFaas 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
- ja veel 1
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
VärbamineFaas 2
- Nebraska Cancer Specialists, Omaha
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Omaha
- Eesnäärmevähk27 uuringut
- Mitteväikerakuline kopsuvähk24 uuringut
- Rinnavähk22 uuringut
- Käär- ja pärasoolevähk18 uuringut
- Vähk (kõik liigid)18 uuringut
- Mittet Hodgkini lümfoom14 uuringut
- Munasarjavähk14 uuringut
- Pankreasevähk14 uuringut
- Pea ja kaela lameepiteeli kartsinoom13 uuringut
- Südamepuudulikkus13 uuringut
- Metastaatiline vähk13 uuringut
- Neeruvähk (neerurakuline kartsinoom)12 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.